Skip to main content
. 2021 Aug 31;14:3509–3518. doi: 10.2147/IDR.S325520

Table 2.

In vitro Activity of Imipenem/Relebactam and Imipenem Against P. Aeruginosa Isolates from ICUs and Non-ICU Wards

Organism/Antimicrobial Agent ICU Origin (IAIs + UTIs + RTIs) Non-ICU Origin (IAIs + UTIs + RTIs)
N S% R% MIC90 N S% R% MIC90
P. aeruginosa
Imipenem/relebactam 441 345 (78.2) 72 (16.3) 32 1445 1243 (86.0) 132 (9.1) 4
Imipenem 441 209 (47.4) 208 (47.2) > 32 1445 842 (58.3) 511 (35.4) 32
Imipenem-non-susceptible P. aeruginosa
Imipenem/relebactam 232 136 (58.6) 72 (31.0) > 32 603 402 (66.7) 132 (21.9) 32
Imipenem 232 0 (0.0) 208 (89.7) > 32 603 0 (0.0) 511 (84.7) > 32
MDR P. aeruginosa
Imipenem/relebactam 229 134 (58.5) 72 (31.4) > 32 606 415 (68.5) 129 (21.3) 32
Imipenem 229 48 (21.0) 169 (73.8) > 32 606 162 (26.7) 400 (66.0) > 32

Abbreviations: IAIs, intra-abdominal infections; ICU, intensive care unit; MDR, multidrug-resistance; MIC, minimum inhibitory concentrations; N, number; R, resistant rate; RTIs, respiratory tract infections; S, susceptible rate; UTIs, urinary tract infections.